Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Richard T. Hoppe(Stanford Medicine), Hema Sundar(National Comprehensive Cancer Network), Joachim Yahalom(Unknown), Bouthaina S. Dabaja, Leo I. Gordon(Northwestern University), Barbara Pro(The University of Texas MD Anderson Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Monika L. Metzger(St. Jude Children's Research Hospital), Matthew M. Poppe(University of Utah), Peter Mauch(Western Sydney University), David B. Mansur(University Hospitals Cleveland Medical Center), Ysabel Durón(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ephraim P. Hochberg(Massachusetts General Hospital), Andres Forero(University of Alabama at Birmingham), Weiyun Z. Ai(City College of San Francisco), Kristie A. Blum(Emory University), Ranjana H. Advani(Stanford Medicine), David Morgan(Vanderbilt University Medical Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Patricia Aoun(University of Nebraska Medical Center), Robert Chen(AstraZeneca (United States)), Joseph O. Moore(Cancer Institute (WIA)), Philip J. Bierman(Susan Thompson Buffett Foundation), Craig H. Moskowitz(University of Miami), Celeste Bello(Moffitt Cancer Center), Jane N. Winter(Northwestern University)
Cited by 99
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k